VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
TBPHTheravance Biopharma, Inc.
$16.56$854M
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksTBPHEarnings History

TBPH logoTheravance Biopharma, Inc. (TBPH) Earnings History

Profitable

15 years of earnings data (2011–2025) · Positive TTM net income

TTM Net Income
$115M
● Profitable
TTM EPS (Diluted)
$2.23
Per share, diluted
YoY EPS Growth
+279.1%
Excellent
Net Margin
98.5%
After-tax profitability
EPS Growth Rate (CAGR)
1YN/A
3YN/A
5YN/A
10YN/A
Operating Margin-12.3%
Gross Margin94.9%
Return on Equity44.8%
Return on Assets25.2%
Record Annual Net Income$872MFY2022
Record Quarterly EPS$12.14Q3 2022
Consecutive Profitable Years1years
Q1 2026
Net Income-$5M
EPS (Diluted)$-0.10
YoY Growth+279.1%Excellent
QoQ Growth-108.1%Declining

Loading earnings history...

Theravance Biopharma, Inc. (TBPH) Earnings Overview

As of June 23, 2026, Theravance Biopharma, Inc. (TBPH) reported trailing twelve-month net income of $115M, reflecting +279.1% year-over-year growth. The company earned $2.23 per diluted share over the past four quarters, with a net profit margin of 98.5%.

Looking at the long-term picture, TBPH's historical earnings data spans multiple years. The company achieved its highest annual net income of $872M in fiscal 2022.

Theravance Biopharma, Inc. maintains industry-leading profitability with a gross margin of 94.9%, operating margin of -12.3%, and net margin of 98.5%. This margin structure demonstrates strong pricing power and operational efficiency. View revenue history →

Compared to peers including INVA ($504M net income, 63.8% margin), PRGO (-$1.82B net income, -33.5% margin), SUPN (-$29M net income, -5.4% margin), TBPH has outperformed on profitability metrics. Compare TBPH vs INVA →

TBPH Earnings vs Peers

Earnings metrics vs comparable public companies

CompanyTTM Net IncomeTTM EPSNet MarginROEYoY GrowthCompare
TBPH logoTBPHCurrent
$115M$2.2398.5%44.8%+279.1%—
INVA logoINVA
$504M$5.9463.8%29.1%+816.7%
PRGO logoPRGO
-$1.8B$-13.10-33.5%-39.3%-723.2%
SUPN logoSUPN
-$29M$-0.50-5.4%-3.7%-151.5%
PCRX logoPCRX
$9M$0.231.0%1.0%+107.4%
INSM logoINSM
-$1.2B$-5.49-210.5%-249.3%-15.1%
Best in group
Lowest in group

TBPH Historical Earnings Data (2011–2025)

15 years
Fiscal Year Net Income YoY % Operating Income EPS (Diluted) Net Margin Op. Margin
2025$106M+287.7%-$13M$2.0698.5%-12.3%
2024-$56M-2.2%-$47M$-1.15-87.6%-72.9%
2023-$55M-106.3%-$56M$-1.00-96.1%-97.6%
2022$872M+537.3%-$92M$-1.261698.5%-179.1%
2021-$199M+28.3%-$258M$-2.87-360.6%-466.1%
2020-$278M-17.6%-$298M$-4.46-386.9%-414.2%
2019-$236M-9.7%-$252M$-4.25-322.1%-343.1%
2018-$216M+24.5%-$239M$-3.99-357.0%-395.5%
2017-$285M-49.7%-$260M$-5.45-1855.0%-1690.6%
2016-$191M-4.6%-$180M$-4.26-391.9%-371.0%
2015-$182M+23.1%-$182M$-5.34-432.6%-431.8%
2014-$237M-51.7%-$233M$-7.46-2028.0%-1989.6%
2013-$156M-1532.2%-$156M$-4.84-69152.2%-69152.2%
2012-$10M+91.2%-$10M$-0.30-7.4%-7.4%
2011-$109M--$109M$-3.43-736.1%-736.1%

Download Data

Export TBPH earnings history in CSV or JSON format

Free sign-in required to download data

Consensus-Based Analysis Tools

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

15+ years return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

TBPH — Frequently Asked Questions

Quick answers to the most common questions about buying TBPH stock.

What is TBPH earnings per share (EPS)?

TBPH trailing twelve-month (TTM) diluted EPS is $2.23, reflecting +279.1% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2011 to 2025 is available in the table on this page.

What is Theravance Biopharma, Inc.'s net income?

Theravance Biopharma, Inc. (TBPH) trailing twelve-month net income is $115M as of 2025. Earnings grew +279.1% year-over-year.

Is TBPH profitable?

Yes, TBPH is profitable with a TTM net income of $115M and a net profit margin of +98.5%.

What is TBPH's earnings growth rate?

TBPH compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2011 to 2025.

What are TBPH's profit margins?

Theravance Biopharma, Inc. net profit margin is +98.5%, operating margin is -12.3%, and gross margin is +94.9%. Above-average net margins reflect strong pricing power and competitive moat. Return on Equity is +44.8%.

Is TBPH growing earnings?

Yes, TBPH earnings are accelerating — EPS growth of +279.1% exceeds the 5-year CAGR of N/A. TTM net income reached $115M. Earnings momentum is strengthening.

What was TBPH's best earnings year?

Theravance Biopharma, Inc.'s highest annual net income on record is $872M, achieved in fiscal year 2022. Earnings history on this page spans 2011 to 2025 and includes all annual and quarterly figures.

What were TBPH's earnings last quarter?

TBPH's most recent reported quarter was Q1 2026. Net income was $-5M with diluted EPS of $-0.10. For a full breakdown of all quarters, see the quarterly earnings table on this page.

TBPH Earnings Over Time (2011–2025)

Net income & EPS — annual and quarterly view